All News Nanexa AB

Equities

Delayed Nasdaq Stockholm Other stock markets 04:16:31 2024-07-18 am EDT			5-day change	1st Jan Change
0.92 ^SEK	+4.55%		+4.41%	-26.83%

Jun. 28	Nanexa AB Announces Chief Financial Officer Changes	CI
Jun. 11	Nanexa AB Announces That First Patient Dosed in Nanexa's Phase I Trial of NEX-22 in Type 2 Diabetes	CI

Nanexa appoints new Chief Financial Officer	Jun. 28	AQ
Nanexa AB Announces Chief Financial Officer Changes	Jun. 28	CI
First patient dosed in Nanexa's Phase I trial of NEX-22 in type 2 diabetes	Jun. 11	AQ
Nanexa AB Announces That First Patient Dosed in Nanexa's Phase I Trial of NEX-22 in Type 2 Diabetes	Jun. 11	CI
Bulletin from Nanexa’s Annual General Meeting	May. 15	AQ
Nanexa AB Elects Hanna Tilus as Members of the Board	May. 15	CI
Nanexa receives approval for NEX-22 clinical study	May. 15	AQ
Nanexa AB Receives Approval for NEX-22 Clinical Study	May. 15	CI
Nanexa Q1 2024 - Insightful capital markets day	May. 10	AQ
Equity Research \| NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential	May. 10	AQ
Nanexa publishes interim report for January-March 2024	May. 03	AQ
Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 03	CI
Invitation to comment on Nanexa's Q1 report 2024	Apr. 30	AQ
Nanexa invites to Capital Markets Day on May 7	Apr. 29	AQ
Approval of clinical trial application for NEX-22 study delayed	Apr. 16	AQ
Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	Apr. 16	CI
Notice of annual general meeting in Nanexa AB (publ)	Apr. 15	AQ
Nanexa publishes annual report for 2023	Mar. 27	AQ
Transcript : Nanexa AB - Special Call	Mar. 07
Nanexa - NEX-22, partner projects, and Novo Nordisk evaluation prioritized	Feb. 22	AQ

No results for this search